Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 49 for your search:
Cancer Type/Condition:
Brain tumor, child: General & other
Stage/Subtype:
childhood embryonal tumor
Country:
U.S.A.
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
3 to 21 at diagnosis
Sponsor:
NCI
Protocol IDs:
COG-ACNS0331
, ACNS0331, NCT00085735
2.
Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Under 3
Sponsor:
NCI
Protocol IDs:
COG-ACNS0334
, ACNS0334, NCT00336024
3.
Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Under 10 at diagnosis
Sponsor:
Other
Protocol IDs:
CHLA-HEAD-START-III
, CHLA-HSIII, CHLA-2004-020, CHLA-04.020, NCT00392886, UMN-MT2004-06
4.
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
3 to 21
Sponsor:
NCI
Protocol IDs:
COG-ACNS0332
, ACNS0332, NCT00392327
5.
Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, or Osteosarcoma
Phase:
Phase III
Type:
Supportive care, Treatment
Status:
Active
Age:
1 to 18
Sponsor:
NCI
Protocol IDs:
COG-ACCL0431
, ACCL0431, NCT00716976
6.
Radiation Therapy and Combination Chemotherapy Followed by Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
3 to 21 at diagnosis
Sponsor:
NCI, Other
Protocol IDs:
CDR0000367486
, SJCRH-SJMB03, NCT00085202
7.
A Phase I/II Study of the Photon Radiosurgery System
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
2 to 32
Sponsor:
Other
Protocol IDs:
CNS 0201
, NCT00179907
8.
Intracerebral Clysis in Treating Patients With Recurrent Primary Brain Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
1 to 120
Sponsor:
Other
Protocol IDs:
R01 CA 89395-01
, Topotecan, Brain Tumors, Intracerebral Clysis, NCT00452959
9.
A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
1 to 17
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
AP23573-07-110
, SUN08-01, NCT00704054
10.
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
1 to 25
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
CHNMC-07053
, 07053, CA180 121, NCT00788125
11.
PF-02341066 in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
1 to 21
Sponsor:
NCI
Protocol IDs:
COG-ADVL0912
, ADVL0912, NCT00939770
12.
Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
1 to 30
Sponsor:
Other
Protocol IDs:
OHSU-5056
, OHSU SOL-08131-L, NCT00983398
13.
Low-Dose Radiation Therapy and Combination Chemotherapy Following Surgery in Treating Children With Newly Diagnosed Primitive Neuroectodermal Tumor or Medulloblastoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
3 to 30 at initial diagnosis
Sponsor:
Other
Protocol IDs:
CHP-693
, CHP-IRB-2001-12-2301, NCI-V01-1680, NCT00031590
14.
Intrathecal Radioimmunotherapy, Radiation Therapy, and Chemotherapy After Surgery in Treating Patients With Medulloblastoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
3 and over
Sponsor:
NCI
Protocol IDs:
MSKCC-02088
, NCT00058370
15.
Proton Beam Radiation Therapy in Treating Young Patients Who Have Undergone Biopsy or Surgery for Medulloblastoma or Pineoblastoma
Phase:
Phase II
Type:
Supportive care, Treatment
Status:
Active
Age:
3 to 21
Sponsor:
NCI, Other
Protocol IDs:
MGH-99-271
, NCT00105560
16.
Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
Phase:
Phase II
Type:
Diagnostic, Treatment
Status:
Active
Age:
21 and under
Sponsor:
NCI
Protocol IDs:
PBTC-022
, NCT00381797
17.
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Any age
Sponsor:
Other
Protocol IDs:
MSKCC-05122
, NCT00445965
18.
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-Cis-Retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
6 months to 21 years
Sponsor:
Other
Protocol IDs:
NYU 05-40 H12853
, PBMTC ONC-032P, NCT00528437
19.
Tumor Lysate Pulsed Dendritic Cell Immunotherapy for Patients With Brain Tumors
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
3368
, NCT00576537
20.
A Phase II Study of Adjuvant Use of Anti-Epidermal Growth Factor Receptor EGFR-425 in High Grade Gliomas
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
15 and over
Sponsor:
Other
Protocol IDs:
12555
, NCT00589706
21.
Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
21 and under
Sponsor:
Other
Protocol IDs:
V0706
, CHRMS# 08-106, PRC # V0706, NCT00601003
22.
Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
21 and under
Sponsor:
Other
Protocol IDs:
CERN08-01
, NCT00883688
23.
Antineoplaston Therapy in Treating Children With Brain Tumors
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
6 months to 17 years
Sponsor:
Other
Protocol IDs:
CDR0000066490
, BC-BT-10, NCT00003458
24.
Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
6 months to 17 years
Sponsor:
Other
Protocol IDs:
CDR0000066513
, BC-BT-22, NCT00003476
25.
Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
3 to 70
Sponsor:
Other
Protocol IDs:
MCW-7594
, MCW-CHW-511, MCW-CHW-9411, NCI-V95-0652, NCT00002647
Select All on Page
1
Help with Results
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
RSS
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
